TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3537596

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole
Number of subjects: 65
Study: 30144986

Group type: EXPERIMENTAL
Intervention: Triple antibiotic solution (1 mg/mL)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Calcium hydroxide/chlorhexidine paste
Number of subjects: 47
Study: 26400827

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 11145

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11145
Study: 25496415

Group type: EXPERIMENTAL
Intervention: Increased dietary α-linolenic acid (ALA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 22766420

Group type: EXPERIMENTAL
Intervention: Spanish version of the SAQLI questionnaire
Number of subjects: 162

Group type: COMPARATOR
Intervention: SF-36, FOSQ, Epworth scale
Number of subjects: 162
Study: 20167306

Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 30
Study: 18090506

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 85
Study: 16864836

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 68
Study: 12568061

Group type: EXPERIMENTAL
Intervention: Modeling time
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Regression adjustment for covariates
Number of subjects: 1188
Study: 10828571

Group type: EXPERIMENTAL
Intervention: Three successive measurements with a 5‐min interval in prone position
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Three successive measurements with a 5‐min interval in supine position
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Single measurement before feeding regardless of body position
Number of subjects: 138
Study: 9097211

Group type: EXPERIMENTAL
Intervention: Immediate caregiver training group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list caregiver training group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Memory retraining group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Caregiver training (all groups)
Number of subjects: 96
Study: 1351405

Group type: EXPERIMENTAL
Intervention: Continuous medication with neuroleptic drugs
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Intermittent medication with crisis intervention
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Intermittent medication with early intervention
Number of subjects: 364

Group type: COMPARATOR
Intervention: Neuroleptic drugs
Number of subjects: 364

Group type: COMPARATOR
Intervention: Low potency neuroleptics
Number of subjects: 364

Group type: COMPARATOR
Intervention: Oral neuroleptics
Number of subjects: 364
Study: 2858619

Group type: EXPERIMENTAL
Intervention: Combination therapy (azathioprine and prednisolone)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Azathioprine withdrawal
Number of subjects: 50
Study: 31869257

Group type: EXPERIMENTAL
Intervention: Glycerol 85%
Number of subjects: 30

Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 30
Study: 31298607

Group type: EXPERIMENTAL
Intervention: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB) associated with Sodium Hyaluronate/Trehalose/Carbomer Gel (HTC-gel)
Number of subjects: 31
Study: 30421481

Group type: EXPERIMENTAL
Intervention: Evolocumab on top of atorvastatin 40 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 26787116

Group type: EXPERIMENTAL
Intervention: SPS (sport students)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: DES (dental students)
Number of subjects: 114
Study: 24113076

Group type: EXPERIMENTAL
Intervention: Standardized CBM‐I
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-generation CBM‐I
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 22449170

Group type: EXPERIMENTAL
Intervention: Massage treatment applied by a physical therapist on the posterior deltoid, infraspinatus, and teres minor for 18 minutes, two times a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received light hand touch on the muscles for 10 minutes, two times a week for 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Massage treatment
Number of subjects: 60
Study: 20851321

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health promotion training (control)
Number of subjects: 0
Study: 17913231

Group type: EXPERIMENTAL
Intervention: Botanical extracts from Epimedium sp.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oestrogenic drugs
Number of subjects: 0
Study: 15156426

Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Self-administered therapy
Number of subjects: 72
Study: 11422149

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS; 200 microg/day)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Budesonide reservoir powder device (BUD RPD; 200 microg/day)
Number of subjects: 440
Study: 9495605

Group type: EXPERIMENTAL
Intervention: Sertraline treatment (11 weeks) in fibromyalgia patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Patients with major depression
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients and major depression patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 41
Study: 8285383

Group type: EXPERIMENTAL
Intervention: Stepwise lowering of hemoglobin concentration through venesections (average decrease from 151 +/- 4 to 121 +/- 3 g/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stepwise lowering of hemoglobin concentration through venesections
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stepwise lowering of hemoglobin concentration through venesections (average volume of about 1.4 liters whole blood within fourteen days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not subjected to venesections)
Number of subjects: 12
Study: 3190968

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at 20 mg h‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.08% bupivacaine infusion at 20 mg h‐1
Number of subjects: 20
Study: 30193564

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 31227852

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-resurfacing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 28689647

Group type: EXPERIMENTAL
Intervention: Pilates method physical activity programme (2 weekly sessions for 8 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no Pilates programme)
Number of subjects: 105
Study: 25261268

Group type: EXPERIMENTAL
Intervention: Home-based telemonitored Nordic walking (NW) training (n=77), five times weekly for eight weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual care alone (control group, n=34)
Number of subjects: 111
Study: 24215511

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel
Number of subjects: 251

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: RRM1 aberrations
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: RRM2B aberrations
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Gene status
Number of subjects: 251
Study: 21692860

Group type: EXPERIMENTAL
Intervention: GEKG
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18165600

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg preoperatively, administered every 6 hours up to a total of 1200 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70
Study: 16728515

Group type: EXPERIMENTAL
Intervention: Apnea divers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 15253736

Group type: EXPERIMENTAL
Intervention: Gentamicin and heparin (5 mg/mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard heparin (5000 IU/mL) alone
Number of subjects: 50
Study: 11739835

Group type: EXPERIMENTAL
Intervention: Cannabinoid receptor agonist nabilone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9415539

Group type: EXPERIMENTAL
Intervention: Modified total lymphoid irradiation plus low dose prednisone (TLI-LDP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham TLI plus identical prednisone therapy (sham TLI-LDP)
Number of subjects: 46
Study: 8512762

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 31
Study: 3687353

Group type: COMPARATOR
Intervention: Neutral recording with no verbal content (Groups I and II)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Experimental recording with a positive suggestion for a rapid recovery (Group III)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Self-prepared message (Group IV)
Number of subjects: 32
Study: 31662387

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Enterococcus faecalis)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open-label placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Concealed placebo treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 120
Study: 27243570

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT), 24 International Units
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25981191

Group type: EXPERIMENTAL
Intervention: SB010 (10 mg, inhalation once daily for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (inhalation once daily for 28 days)
Number of subjects: 40
Study: 24038301

Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy and psychotherapy
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: MADRS total score and subscales
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Four-factor model (Sadness, Negative Thoughts, Detachment, Neurovegetative symptoms)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Hierarchical model of four factors
Number of subjects: 821
Study: 21385504

Group type: EXPERIMENTAL
Intervention: Spiced rice meal
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Apple pie yogurt
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Retro-nasal aroma release measurement
Number of subjects: 54
Study: 19620438

Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 53457

Group type: EXPERIMENTAL
Intervention: Quality assurance procedures
Number of subjects: 53457
Study: 16874872

Group type: EXPERIMENTAL
Intervention: S. boulardii (250 mg bid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (ORS and nutritional support only)
Number of subjects: 100
Study: 12972483

Group type: EXPERIMENTAL
Intervention: Standardised training on rubber mannequins
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Additional training on patients in hospital joint injection clinics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standardised training only)
Number of subjects: 40
Study: 10633535

Group type: EXPERIMENTAL
Intervention: DHEA (200 to 500 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8733067

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Converting-enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flosequinan (direct-acting vasodilator)
Number of subjects: 0
Study: 8262783

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 3853573

Group type: EXPERIMENTAL
Intervention: Experiential learning through home visits to elderly clients (group A: healthy clients at home, group B: hospitalized clients recuperating at home) over a 3-month period.
Number of subjects: 0
Study: 28001465

Group type: EXPERIMENTAL
Intervention: Acreos Adapt AO
Number of subjects: 83

Group type: COMPARATOR
Intervention: Acrysof SA60AT
Number of subjects: 83
Study: 26872709

Group type: EXPERIMENTAL
Intervention: Cleave techniques (various)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 200 μm fiber
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 365 μm fiber
Number of subjects: 5
Study: 24746649

Group type: EXPERIMENTAL
Intervention: Fluoroscopy at 7.5 FPS
Number of subjects: 363
Study: 22698292

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) administered at 2 atm twice a day for 40 treatments as an adjunct to surgery and antibiotics
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional therapy alone (surgery and antibiotics)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 46
Study: 20926017

Group type: EXPERIMENTAL
Intervention: Gentacoll implants (10 × 10 × 0.5 cm, 280 mg collagen sponge plus 200 mg gentamicin sulphate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no Gentacoll application)
Number of subjects: 44
Study: 18926150

Group type: EXPERIMENTAL
Intervention: 80 mg/d of atorvastatin (high-dose regimen)
Number of subjects: 10001

Group type: COMPARATOR
Intervention: 10 mg/d of atorvastatin (low-dose regimen)
Number of subjects: 10001
Study: 15894964

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/d for 3 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12464207

Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine (without vasoconstrictor)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 2% lignocaine (with adrenaline 1:80,000)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 93
Study: 12470125

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 115
Study: 9713273

Group type: EXPERIMENTAL
Intervention: Bolus 5‐FU injection (2-4 min)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Short-term 5‐FU infusion (10-20 min)
Number of subjects: 203
Study: 7994982

Group type: EXPERIMENTAL
Intervention: 200 mg ticlopidine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100 mg ticlopidine and 60-150 mg acetylsalicylic acid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 200 mg cilostazol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (all groups combined)
Number of subjects: 48
Study: 2903927

Group type: EXPERIMENTAL
Intervention: Sulfasalazine 2 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or Sulfasalazine 0.5 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfasalazine 1 g/day or 2 g/day
Number of subjects: 0
Study: 31722313

Group type: EXPERIMENTAL
Intervention: Perampanel, a selective non‐competitive AMPA receptor antagonist, administered for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28551714

Group type: EXPERIMENTAL
Intervention: Cue avoidance training (CAT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Inhibitory control training (ICT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham (control) CAT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham (control) ICT
Number of subjects: 120
Study: 25630007

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 28

Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 28
Study: 23312822

Group type: EXPERIMENTAL
Intervention: True anteroposterior (GH AP) view
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional AP view
Number of subjects: 160
Study: 21245794

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC‐MPS)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 396
Study: 18452622

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation for 5 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation for 15 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 0
Study: 16226397

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy with CMF chemotherapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Sequential radiotherapy with CMF chemotherapy
Number of subjects: 206
Study: 12876090

Group type: COMPARATOR
Intervention: β-carotene (20 mg)
Number of subjects: 25563

Group type: COMPARATOR
Intervention: α-tocopherol (50 mg)
Number of subjects: 25563
Study: 10926587

Group type: EXPERIMENTAL
Intervention: Active inhaler
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 400
Study: 9594145

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg a day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not treated with perindopril)
Number of subjects: 46
Study: 1399429

Group type: EXPERIMENTAL
Intervention: Soy/marine oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrandomized group of formula-fed full-term infants
Number of subjects: 0
Study: 29449079

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study: 29206339

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (25 healthy age-matched subjects)
Number of subjects: 46
Study: 26544854

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham radial extracorporeal shock wave therapy (sham rESWT)
Number of subjects: 56
Study: 24997050

Group type: COMPARATOR
Intervention: Tai Chi group (D group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Swimming group (A group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Running group (B group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Square dancing group (C group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (E group)
Number of subjects: 150
Study: 22595151

Group type: EXPERIMENTAL
Intervention: Dispersible formulation of risperidone (2 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Branded formulation of risperidone (2 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 22
Study: 20622661

Group type: EXPERIMENTAL
Intervention: Early drain removal (POD 3)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard drain removal (POD 5 or beyond)
Number of subjects: 114
Study: 16923324

Group type: EXPERIMENTAL
Intervention: Typical antipsychotics
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Risperidone or Olanzapine
Number of subjects: 30
Study: 16142041

Group type: EXPERIMENTAL
Intervention: Insulin treatment (alone or in combination with oral antidiabetic drugs)
Number of subjects: 2150000

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 2150000
Study: 12084083

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK 506) applied 30 min after sodium lauryl sulphate (SLS) irritation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK 506) applied 1 x daily for 5 days after the 4-day irritation period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK 506) in the UVB erythema model
Number of subjects: 0
Study: 10027655

Group type: COMPARATOR
Intervention: 50 microg inhaled salmeterol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg oral bambuterol
Number of subjects: 16
Study: 7595704

Group type: EXPERIMENTAL
Intervention: CHOP (doxorubicin)
Number of subjects: 145

Group type: COMPARATOR
Intervention: CNOP (mitoxantrone)
Number of subjects: 145
Study: 2202513

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 to 4 gm/day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Cefoxitin (4 to 8 gm/day)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 266

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 266
Study: 7211276

Group type: EXPERIMENTAL
Intervention: Scanlens 75 high water content lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bausch & Lomb Soflens U3 low water content lenses
Number of subjects: 0
Study: 30685318

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical testing (FIT) with appropriate colonoscopy follow-up
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual care clinics
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lagged data accounting for implementation delay
Number of subjects: 8
Study: 28103698

Group type: EXPERIMENTAL
Intervention: Histamine (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26580986

Group type: EXPERIMENTAL
Intervention: Black women
Number of subjects: 71

Group type: COMPARATOR
Intervention: White women
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: BPI-interference scores
Number of subjects: 71
Study: 25027109

Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin tablets (once daily for 1 year)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo (once daily for 1 year)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin tablets (dosing at bedtime or with dinner)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin tablets
Number of subjects: 129
Study: 21997930

Group type: EXPERIMENTAL
Intervention: K.C. (individual with episodic amnesia)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Controls (individuals without episodic amnesia)
Number of subjects: 1